Analystreport

Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald.

Halozyme Therapeutics, Inc.  (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx